SEC Info - Allogene Therapeutics, Inc.

SEC Info℠

Home

Help

Please Sign In

Allogene Therapeutics, Inc. – ‘8-K’ for 3/14/24

On: Thursday, 3/14/24, at 4:10pm ET · For: 3/14/24 · Accession #: 1737287-24-19 · File #: 1-38693

  As Of               Filer                 Filing    For·On·As Docs:Size

 3/14/24  Allogene Therapeutics, Inc.       8-K:2,9     3/14/24   11:236K

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     25K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     71K 
 6: R1          Document and Entity Information Document            HTML     45K 
 8: XML         IDEA XML File -- Filing Summary                      XML     11K 
11: XML         XBRL Instance -- allo-20240314_htm                   XML     13K 
 7: EXCEL       IDEA Workbook of Financial Report Info              XLSX      8K 
 4: EX-101.LAB  XBRL Labels -- allo-20240314_lab                     XML     62K 
 5: EX-101.PRE  XBRL Presentations -- allo-20240314_pre              XML     33K 
 3: EX-101.SCH  XBRL Schema -- allo-20240314                         XSD     10K 
 9: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    17K 
10: ZIP         XBRL Zipped Folder -- 0001737287-24-000019-xbrl      Zip     25K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX:

allo-20240314

i 0001737287 i false00017372872024-03-142024-03-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________

FORM i 8-K

____________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): i March 14, 2024

_______________________

i Allogene Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

____________________________


i Delaware	i 001-38693	i 82-3562771
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

i 210 East Grand Avenue, i South San Francisco, i California i 94080

(Address of principal executive offices including zip code)

Registrant’s telephone number, including area code: ( i 650) i 457-2700

(Former name or former address, if changed since last report.)

________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


			i ☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
			i ☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
			i ☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
			i ☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

i Common Stock, $0.001 par value per share

i ALLO

i The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On March 14, 2024, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the fourth quarter and year ended December 31, 2023 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.


(d) Exhibits
Exhibit Number						Description
99.1						Press Release of the Company, dated March 14, 2024.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



			ALLOGENE THERAPEUTICS, INC.

			By:			/s/ *David Chang, M.D., Ph.D.*
						David Chang, M.D., Ph.D.
						President, Chief Executive Officer

Dated: March 14, 2024

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period end:	3/14/24	10-K/A
	12/31/23
		List all Filings

↑Top

Filing Submission 0001737287-24-000019 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)